Okta is postponing product updates and internal projects for 90 days to enhance its security architecture. CEO Todd McKinnon stated in an earnings call that security is the company’s highest priority, emphasizing their commitment to protect current and future customers.
Processa Acquisition Lands Immunology Drug That Could Rival a New Novartis Product
With the merger, Processa’s new lead asset is a Vidya Therapeutics immunology drug that offers pipeline-in-a-product potential addressing a target that has clinical and regulatory
